Literature DB >> 20738939

Prevalence of atrial fibrillation and use of antithrombotics in hypertensive patients aged >or=65 years. The FAPRES trial.

Pedro Morillas1, Vicente Pallarés, José Luis Llisterri, Carlos Sanchis, Tomás Sánchez, Lorenzo Fácila, Manuel Pérez-Alonso, Jesús Castillo, Josep Redón, Vicente Bertomeu.   

Abstract

INTRODUCTION AND
OBJECTIVES: Age and arterial hypertension are two of the main factors associated with atrial fibrillation and an increased risk of embolism. The objective of this study was to determine the prevalence of atrial fibrillation and the extent of antithrombotic use in hypertensive patients aged >or=65 years in the Spanish region of Valencia.
METHODS: Each study investigator enrolled the first three hypertensive patients aged >or=65 years who came for a consultation on the first day of each week for 5 weeks. Each patient's risk factors, history of cardiovascular disease, CHADS2 score and medical treatment were noted and an ECG was recorded. Data were analyzed centrally. A patient was regarded as having atrial fibrillation if it was observable on the ECG or reported in medical records.
RESULTS: The study included 1,028 hypertensive patients with a mean age of 72.8 years. Overall, 10.3% had atrial fibrillation: in 6.7%, it was observable on the ECG while 3.6% were in sinus rhythm but had a history of the condition. Factors associated with atrial fibrillation were age, alcohol intake, structural heart disease and glomerular filtration rate. In total, 76.2% of patients with ECG evidence of atrial fibrillation and a CHADS2 score >1 were taking anticoagulants compared with 41.7% of those who had a history of the condition but were currently in sinus rhythm.
CONCLUSIONS: The prevalence of atrial fibrillation in our group of hypertensives was 10.3%; in 1.7%, it was previously undiagnosed. Antithrombotic use was high in patients with current atrial fibrillation, but lower in those who had experienced an episode previously.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738939     DOI: 10.1016/s1885-5857(10)70188-2

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  5 in total

Review 1.  Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

Authors:  Antoni Martínez-Rubio; Mario DiazNuila Alcazar; Anna Soria Cadena; Roger Martínez-Torrecilla
Journal:  Eur Cardiol       Date:  2016-12

2.  Gender differences related to the presence of atrial fibrillation in older hypertensive patients.

Authors:  Lorenzo Fácila; Vicente Pallarés; Pedro Morillas; Alberto Cordero; Jose Luis Llisterri; Carlos Sánchis; Jose L Gorriz; Jesus Castillo; Vicente Gil; Josep Redon
Journal:  World J Cardiol       Date:  2013-05-26

3.  N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Populations Carrying Cardiovascular Risk Factors.

Authors:  Elena Palà; Alejandro Bustamante; Josep Lluis Clúa-Espuny; Juan Acosta; Felipe Gonzalez-Loyola; Juan Ballesta-Ors; Natalia Gill; Andrea Caballero; Jorge Pagola; Alonso Pedrote; Miguel Angel Muñoz; Joan Montaner
Journal:  Front Neurol       Date:  2019-11-29       Impact factor: 4.003

4.  Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA.

Authors:  Anna Panisello-Tafalla; Josep Lluís Clua-Espuny; Vicente F Gil-Guillen; Antonia González-Henares; María Lluisa Queralt-Tomas; Carlos López-Pablo; Jorgina Lucas-Noll; Iñigo Lechuga-Duran; Rosa Ripolles-Vicente; Jesús Carot-Domenech; Miquel Gallofré López
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

5.  [The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study].

Authors:  Emmanuel Giménez-García; Josep Lluís Clua-Espuny; Ramón Bosch-Príncep; Carlos López-Pablo; Iñigo Lechuga-Durán; Miquel Gallofré-López; Anna Panisello-Tafalla; Jorgina Lucas-Noll; Maria Lluisa Queralt-Tomas
Journal:  Aten Primaria       Date:  2013-09-14       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.